Huifang Li

发表

Discovery of novel androgen receptor inhibitors as prospective therapeutics for advanced prostate cancer

Huifang Li, 2015 .

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.

P. Rennie, F. Ban, A. Cherkasov, 2014, Journal of medicinal chemistry.

Small Molecule Therapeutics Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer

P. Rennie, Kriti Singh, A. Cherkasov, 2013 .

Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)

Steven J. M. Jones, S. Dunn, A. Cherkasov, 2013, Oncotarget.

Selectively Targeting the DNA-binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer*

P. Rennie, F. Ban, Kriti Singh, 2014, The Journal of Biological Chemistry.

The molecular basis for SARS-CoV-2 recognized by dog ACE2

Y. Bi, Qihui Wang, J. Qi, 2021 .

Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma

Jing Yu, Huifang Li, Yujie Zhao, 2022, Frontiers in Pharmacology.

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.

P. Rennie, J. Peacock, F. Ban, 2018, Cancer letters.

Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.

Artem Cherkasov, Eric Leblanc, Kate Frewin, 2013, Journal of medicinal chemistry.

Targeting the Androgen Receptor Signaling Axis

P. Rennie, A. Cherkasov, Huifang Li, 2017 .

Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).

P. Rennie, F. Ban, A. Cherkasov, 2014, Journal of medicinal chemistry.

Serine protease HtrA1 as an inhibitor on proliferation invasion and migration of gastric cancer

Huifang Li, Wenzhao Zhao, Wan-Ting Xu, 2015, Medical Oncology.

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions

M. Gleave, Rendong Yang, P. Rennie, 2017, Molecular Cancer Therapeutics.

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors

P. Rennie, F. Ban, Kriti Singh, 2015, Cells.

Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.

P. Rennie, F. Ban, A. Cherkasov, 2018, European journal of medicinal chemistry.

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

P. Rennie, F. Ban, Kriti Singh, 2015, The Journal of Biological Chemistry.

Best Practices of Computer-Aided Drug Discovery: Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action

Artem Cherkasov, Huifang Li, Fuqiang Ban, 2017, J. Chem. Inf. Model..

A Non-Synonymous Coding Variant (L616F) in the TLR5 Gene Is Potentially Associated with Crohn's Disease and Influences Responses to Bacterial Flagellin

A. Cherkasov, T. Steiner, D. Mack, 2013, PloS one.

Identification of Novel Androgen Receptor Antagonists Using Structure- and Ligand-Based Methods

Artem Cherkasov, Huifang Li, Xin Ren, 2013, J. Chem. Inf. Model..

Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer

Artem Cherkasov, Peyman Tavassoli, Paul S. Rennie, 2013, Molecular Cancer Therapeutics.